317 related articles for article (PubMed ID: 23838005)
1. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.
Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
FEBS Lett; 2011 Jun; 585(12):1884-90. PubMed ID: 21557940
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
Funakoshi-Tago M
Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
[TBL] [Abstract][Full Text] [Related]
4. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
6. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
7. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
8. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
[TBL] [Abstract][Full Text] [Related]
9. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
[TBL] [Abstract][Full Text] [Related]
10. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
11. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
12. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway].
Funakoshi-Tago M
Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
17. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
Oh ST; Gotlib J
Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
[TBL] [Abstract][Full Text] [Related]
19. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
[TBL] [Abstract][Full Text] [Related]
20. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
